Video

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

Biology is complicated. Our scientists work with large amounts of scientific data to better understand the relationship between biological entities.

Many of these pieces form a coherent picture about one segment of the biology in question, but often, scientists are presented with conflicting evidence. There are many gaps in the understanding of biology and many blanks remain to be filled. Understanding and filling these gaps is incredibly important for scientists to be able to select the right targets.  

At Benevolent we use various computational technologies and a range of standard and non-standard design patterns to help drug discoverers explore and select the best targets for validation. The role of our machine learning researchers, engineers and designers is to build this technology that helps our scientists break though this vastness of biological information to develop medicines for the patients that need them most.  

Marek, Lead Product Designer, gives a talk at World Usability Day Silesia 2019 in which explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020